

Preparing Pharmacists for the New and Emerging Treatment Landscape of Waldenström Macroglobulinemia



November 30, 2021 • 6:00PM – 7:00PM ET

PTCE invites you to a Live Free Accredited Presentation

EDUCATIONAL OBJECTIVES

After completion of this activity, pharmacists will be able to:

- Examine the pathophysiology of Waldenström macroglobulinemia and its connection to use of new and emerging drug therapies
- Apply knowledge of clinical guidelines to treatment selection in patients with Waldenström macroglobulinemia
- Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia

After completion of this activity, pharmacy technicians will be able to:

- Outline clinical presentation and complications of Waldenström macroglobulinemia
- Review oral oncolytics used in the treatment of Waldenström macroglobulinemia
- List common adverse effects associated with therapies used for Waldenström macroglobulinemia

FACULTY



Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Ambulatory Hematology Oncology
University of Michigan Rogel Cancer Center
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, MI

Victoria is a Clinical Pharmacist Specialist in Hematology at the Michigan Medicine Rogel Cancer Center and an adjunct clinical professor at the University of Michigan College of Pharmacy. She completed her Doctor of Pharmacy at the University at Buffalo, followed by residency training at the University of Michigan and is a Board-Certified Hematology/Oncology Pharmacist. She primarily cares for patients with both malignant and benign hematological disorders. Her research focuses on improving clinical outcomes in hematology patients, oncology stewardship, and expanding the role of the oncology pharmacist.

ACCREDITATION STATEMENT



Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-21-312-L01-P and 0290-0000-21-364-L01-T. The activity is available for CE credit through January 30, 2022.

This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc.

Learn more at www.pharmacytimes.org

PTce